Fei Chen | Synthetic Biology | Cost-effectiveness Award

Fei Chen | Synthetic Biology | Cost-effectiveness Award

Dr. Fei Chen, Beijing Institute of Genomics, China.

Publication profile

Scopus
Googlescholar

Education

    • Ph.D. in Biology (Institution: CAS) 🎓
    • Postdoctoral Researcher in Genomics 🔬

Experience

    • Professor (PI) at Beijing Institute of Genomics, CAS 🏫
    • Chief Scientist, National Key R&D Program 🧑‍🔬
    • Editorial Board Member of multiple international journals 📚
    • Principal Investigator for over 30 funded research projects 💼

Suitability For The Award

Dr. Fei Chen is an outstanding candidate for the Cost-Effectiveness Award due to his ability to maximize scientific impact and innovation while efficiently utilizing resources. His exemplary track record of high-impact research in genomics, biosecurity, and synthetic biology demonstrates strategic allocation of funding and significant contributions to addressing critical global health challenges. Dr. Chen’s leadership in research projects, prolific publication record, and innovative patents showcase his commitment to advancing science with optimal resource management.

Professional Development 

Awards and Honors

  • Chinese Medical Science and Technology Award 🏆
  • Huaxia Medical Science and Technology Award 🏅
  • CAS “Hundred Talents Program” (Category A) Recruitment 🎖️
  • National Key R&D Program Chief Scientist 👨‍🔬
  • Over 20 authorized patents, including 4 PCT patents 📜

Publications

  • Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024 – Nucleic Acids Research, 2024, 52(1 D), cited by 50 📚🧬
  • HervD Atlas: A curated knowledgebase of associations between human endogenous retroviruses and diseases – Nucleic Acids Research, 2024, 52(D1), cited by 5 🔬🧪
  • Spatiotemporal single-cell transcriptomic profiling reveals inflammatory cell states in a mouse model of diffuse alveolar damage – Exploration, 2023, 3(3), cited by 11 🐁🔍
  • Comparative transcriptome analysis of SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoV-229E identifying potential IFN/ISGs targets for inhibiting virus replication – Frontiers in Medicine, 2023, 10, cited by 0 🦠🧑‍⚕️
  • Genomic epidemiology and heterogeneity of Providencia and their bla NDM-1-carrying plasmids – Emerging Microbes and Infections, 2023, 12(2), cited by 4 🧬🦠
  • Proteomic analyses of smear-positive/negative tuberculosis patients uncover differential antigen-presenting cell activation and lipid metabolism – Frontiers in Cellular and Infection Microbiology, 2023, 13, cited by 0 🩺💊
  • Comparative genomic analysis reveals differential genomic characteristics and featured genes between rapid- and slow-growing non-tuberculous mycobacteria – Frontiers in Microbiology, 2023, 14, cited by 0 🧫🔬